The Oncology Institute, Inc. TOI Ratios & Valuation
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Operating margin | -6%+6.9pp | -7.2%+8.1pp | -8.9%+7.8pp | -11.1%+6.5pp | -12.9%+5.2pp | |
| Net margin | -8%+8.0pp | -12.1%+4.4pp | -14.4%+4.2pp | -15.5%— | -16%— | |
| EBITDA margin | -4.7%+6.5pp | -5.8%+7.9pp | -7.4%+7.7pp | -9.4%+6.4pp | -11.3%+5.1pp | |
| Returns | ||||||
| Return on assets | -26.2%+8.7pp | -35.9%-2.1pp | -38.7%-3.3pp | -38.8%— | -34.9%— | |
| Return on invested capital | -51.8%+2.1pp | -54.8%-0.3pp | -53.1%-2.9pp | -52.7%-8.3pp | -53.9%-15.0pp | |
| Efficiency | ||||||
| Asset turnover | 3.3×+1.1× | 3×+0.9× | 2.7×+0.8× | 2.5×+0.7× | 2.2×+0.6× | |
| Liquidity | ||||||
| Current ratio | 1.5×-0.3× | 1.6×-0.6× | 1.7×-0.8× | 1.6×-1.7× | 1.8×-1.3× | |
| Quick ratio | 1.2×-0.4× | 1.4×-0.6× | 1.4×-0.9× | 1.4×-1.6× | 1.6×-1.2× | |
| Cash ratio | 0.4×-0.3× | 0.5×-0.5× | 0.4×-0.6× | 0.5×-0.6× | 0.7×-0.1× | |
| Leverage | ||||||
| Debt-to-assets | 0.6×0.0× | 0.6×-0.1× | 0.6×-0.1× | 0.6×0.0× | 0.6×0.0× | |
| Interest coverage | -4.3×+0.4× | -3.2×+4.8× | -3.9×+3.8× | -4.3×— | -4.7×— | |
| Per Share | ||||||
| Book value per share | -$0.16-344% | -$0.17-456% | -$0.13-161% | -$0.10-125% | $0.07-88.2% | |
| Valuation | ||||||
| Market capitalization | $511.91M+133% | $350.24M+1,400% | $326.33M+1,222% | $216M+528% | $100.05M-14.7% | |
| Enterprise value | $586.58M+108% | $420.42M+334% | $402.33M+301% | $288.98M+143% | $162.74M-19.1% | |
| Price / sales | 0.9×+0.4× | 0.7×+0.6× | 0.7×+0.6× | 0.5×+0.4× | 0.2×-0.1× | |
| EV / sales | 1.1×+0.4× | 0.8×+0.6× | 0.9×+0.6× | 0.7×+0.4× | 0.4×-0.2× | |
| Earnings yield | -8.5%+20.8pp | -17.3%+260pp | -20.3%+264pp | -30.5%— | -64.3%— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where do The Oncology Institute, Inc.'s ratios come from?
- Every ratio is computed from The Oncology Institute, Inc.'s SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
